BioSpace

Makary Got His Man in Pazdur—But Can He Last as CDER Director?

A week into his tenure as head of the FDA’s Center for Drug Evaluation and Research, experts agree that Rick Pazdur is the “ideal fit” to stabilize the agency. And, according to one ex-FDA official, ...
Neurology Advisor

Dr Richard Pazdur Appointed to Lead FDA’s Drug Division After Turbulent Year

The FDA has appointed one of its most respected cancer drug regulators to lead the agency’s main division for approving new drugs.
Healio

FDA taps ‘visionary’ oncology leader to serve as top drug regulator

The FDA on Nov. 11 appointed Richard Pazdur, MD, as the new director of the Center for Drug Evaluation and Research.Pazdur ...
HealthLeaders Media

FDA announces agency veteran will become top drug regulator after Tidmarsh resignation

The FDA on Tuesday announced 26-year agency veteran Richard Pazdur will replace a top regulator who resigned earlier this month amid accusations of abusing his power. Pazdur will be the director of ...
Clinical Trials Arena on MSN

FDA’s revolving door reveals Pazdur as new CDER head

"FDA’s revolving door reveals Pazdur as new CDER head" was originally created and published by Clinical Trials Arena, a ...
Food Safety News

Better FDA Act offers ingredient oversight, but it might work ‘like a lobster trap’

KS, has introduced The Better Food Disclosure Act (The Better FDA), a to reform the “Generally Recognized as Safe” or “GRAS” ...
Seeking Alpha

Top FDA official Tidmarsh resigns after comments on kidney drug, HHS probe

George Tidmarsh has lost his job as director of the U.S. FDA's Center for Drug Evaluation and Research amid accusations that he leveled false statements against a Canadian drugmaker and disparaged one ...
FiercePharma

CDER chief George Tidmarsh resigns as deleted LinkedIn post prompts Aurinia lawsuit, FDA probe

High-ranking FDA official George Tidmarsh, M.D., Ph.D., has tendered his resignation after an unconventional LinkedIn diatribe landed the senior drug regulator at the center of a lawsuit and an ...
BioWorld

FDA’s CDER helmless again, amid bribery, defamation claims

The U.S. FDA once again has a leadership gap at the top of its drug center, which already has been ravaged this year by massive terminations, resignations and retirements of senior leaders. George ...
BioWorld

Three months later, FDA’s CDER helmless again

The U.S. FDA once again has a leadership gap at the top of its drug center. George Tidmarsh, a biopharma industry veteran who’s helmed CDER for a little more than three months, resigned yesterday ...
JD Supra

Shutdown Updates, FDA Orphan Drug Leader Reassigned as CMS Issues Orphan Drugs Guidance, FDA to Host Allergen Threshold Meeting, and Commissioner’s National Priority Review ...

Through our Venable FDA Pulse series, we provide insight into key developments within the Food and Drug Administration (FDA or the Agency), emerging trends, enforcement activity, and other topics ...
AOL

FDA Stayed Silent As Internal Reports About Potential Tylenol Risks Piled Up

The Food and Drug Administration (FDA) defied the advice of its own drug safety experts to warn pregnant women about Tylenol for nearly a decade, internal reports and presentations obtained by the ...